1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
Sandu Pharmaceuticals Limited

Sandu Pharmaceuticals Limited

BBSE:SANDUPHQ
33.00
INR
-1.51
(-4.38%)
1.78EPS
23.08P/E
396.10MMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
50.78
55.93
58.01
60.48
69.22
69.8
68.31
82.96
82
74.17
69.64
69.55
72.39
69.84
Basic EPS, GAAP
0.7
0.58
0.76
-0.63
0.79
0.94
1.02
1.54
1.99
1.73
1.51
1.6
1.83
1.78
Free Cash Flow per Basic Share
-1.49
6.71
-2.23
6.08
0.77
5.13
8.6
10.54
0.13
-0.96
-0.69
0.01
5.58
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
0.4
0.75
0.75
0.8
0.8
- -
Book Value per Share
25.72
25.63
39.06
38.71
39.66
40.66
41.29
42.28
41.4
40.62
42.02
43.49
45.21
- -
Tangible Book Value per Share
25.72
25.63
38.95
38.46
39.43
40.48
41.15
42.2
41.36
40.57
41.98
43.47
45.12
- -
Basic Weighted Avg Shares
7
7
7
7
7
7
7
7
8
9
10
10
10
10
Sales/Revenue/Turnover
360
396
411
428
490
494
484
587
655
653
673
672
699
696
Operating Margin (%)
4.32
4.7
5.45
2.58
3.9
3.18
2.03
2.73
3.58
3.01
2.55
3.11
3.76
3.37
Depreciation Expense
5
11
7
9
6
6
6
6
5
5
6
7
7
7
Net Income, GAAP
5
4
5
-4
6
7
7
11
16
15
15
15
18
18
Effective Tax Rate (%)
39.73
34.21
20.83
933.05
25.65
34.25
21.62
35
31.39
31.41
29.51
28.15
33.49
33.89
Profit Margin (%)
1.38
1.04
1.31
-1.04
1.15
1.35
1.49
1.86
2.43
2.33
2.17
2.31
2.53
2.54
Working Capital
111
113
110
98
55
62
111
180
118
117
117
142
149
- -
LT Debt
17
12
8
1
2
2
- -
- -
- -
- -
1
4
3
- -
Total Equity
182
181
277
274
281
288
292
335
365
392
406
420
437
- -
Return on Invested Capital (%)
1.41
1.4
1.51
-19.88
3.86
2.85
2.34
3.22
4.46
3.44
2.91
3.44
3.46
- -
Return on Capital (%)
4.18
4.46
5.16
-32.43
3.81
3.55
3.17
3.55
4.76
4.15
3.75
3.89
4.24
- -
Return on Common Equity (%)
2.76
2.28
2.35
-1.61
2.02
2.35
2.48
3.48
4.54
4.02
3.66
3.75
4.12
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
1
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
3
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
10
10
10
Market Capitalization
362
295
396

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
253
- -
Cash, Cash Equivalents & STI
- -
69
- -
Accounts Receivable, Net
- -
54
- -
Inventories
- -
105
- -
Total Current Liabilities
- -
104
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
1
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.76%
5.48%
3.94%
Free Cash Flow
4,249.52%
8,460.61%
43,412.1%
Net Income, GAAP
-27.32%
11.46%
14.03%
Sales/Revenue/Turnover
5.7%
3.64%
4.08%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
170
177
184
141
672
2026
167
176
188
169
699
2027
164
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
0.17
0.52
0.57
0.34
1.6
2026
0.23
0.54
1.01
0.04
1.83
2027
0.24
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
0.8
2026
- -
- -
- -
- -
0.8
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Balram Viswananthan
Full Time Employees
258
Sector
Health technology
Industry
Pharmaceuticals: other
Address
P.B. No. 17201 Mumbai MA India 400071
IPO Date
Sep 26, 1994
Website
sandu.in
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
Sandu Pharmaceuticals Limited manufactures and markets Ayurvedic medicines under the SANDU brand, offering a portfolio of over 150 products across 15 therapeutic segments including digestive health such as Berbenteron suspension, Berbenteron tablets, Bilagyl, Debix, Pregutero, Sarak, Stresan, Jaundex, Whoopin and Pentazyme; respiratory health; gynecology and obstetrics; pediatrics; liver care such as Vanari Kalpa; neurology; male reproductive health including Vimfix for vigor and vitality; urinary disorders; arthritic conditions; cardiovascular support; skincare and haircare like Elegance Oil; muscle and bone health such as Osteon D and Haemol Forte; immunity boosters; wellness products covering female wellness, male wellness and mother-child care; and lifestyle disorder remedies; with manufacturing utilizing in-house know-how from Sandu Brothers Private Limited and sales through e-commerce and traditional channels in India and internationally. Founded on May 10, 1899 and headquartered in Mumbai with facilities in Chembur, New Mumbai and Goa, the company operates as a debt-free entity with ISO 9001:2000 certification for its production and research units including Sandu Research Foundation Pvt Ltd. In fiscal year 2023-24 ended March 31, 2024, it reported revenue growth of 2.96% while net profit declined 3.90%, declared a final dividend of 0.80 paise per share representing 8% on paid-up capital, reconstituted its board with retirements of several independent directors including Chairman Vinay Kumar Kottapalli and appointments such as CA Balram Viswanathan as Chairman, Adv Ajit R Kantak, Vijay Kottapalli as additional non-executive independent director for a five-year term from August 12, 2024 and Smt Jayshree Sandu as non-executive non-independent women director from September 30, 2024, increased statutory auditor remuneration, ratified cost auditor fees and pursues strategic priorities of domestic and international market expansion via digital platforms and partnerships, enhanced research and innovation, customer engagement and sustainable practices including eco-friendly packaging and organic sourcing.